{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:11:41Z","timestamp":1761718301383},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1002\/jps.23910","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T09:32:40Z","timestamp":1393839160000},"page":"1400-1410","source":"Crossref","is-referenced-by-count":5,"title":["Investigation of Cenderitide Controlled Release Platforms for Potential Local Treatment of Cardiovascular Pathology"],"prefix":"10.1016","volume":"103","author":[{"given":"Xu Wen","family":"Ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerh Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddy Y.C.","family":"Boey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subbu S.","family":"Venkatraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1002\/jps.23910_bb0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","article-title":"Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP","volume":"52","author":"Lisy","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"50","key":"10.1002\/jps.23910_bb0015","doi-asserted-by":"crossref","first-page":"35003","DOI":"10.1074\/jbc.M804538200","article-title":"Novel bifunctional natriuretic peptides as potential therapeutics","volume":"283","author":"Dickey","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1002\/jps.23910_bb0020","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.yjmcc.2011.03.013","article-title":"Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation","volume":"51","author":"Dickey","year":"2011","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10.1002\/jps.23910_bb0025","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0008-6363(02)00402-9","article-title":"Dendroaspis natriuretic peptide relaxes isolated human arteries and veins","volume":"55","author":"Burnett","year":"2002","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1002\/jps.23910_bb0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1177\/0091270009336233","article-title":"Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects","volume":"49","author":"Lee","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"27","key":"10.1002\/jps.23910_bb0035","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.0811851106","article-title":"Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide","volume":"106","author":"Pan","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1002\/jps.23910_bb0040","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1172\/JCI116800","article-title":"Vasonatrin peptide\u2014A unique synthetic natriuretic and vasorelaxing peptide","volume":"92","author":"Wei","year":"1993","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1002\/jps.23910_bb0045","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ahj.2004.05.027","article-title":"Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure","volume":"148","author":"Aronson","year":"2004","journal-title":"Am Heart J"},{"issue":"2","key":"10.1002\/jps.23910_bb0050","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1253\/circj.68.95","volume":"68","author":"Asakura","year":"2004","journal-title":"Circ J"},{"issue":"E","key":"10.1002\/jps.23910_bb0055","doi-asserted-by":"crossref","first-page":"E18","DOI":"10.1093\/eurheartj\/sul026","article-title":"Clinical application of the natriuretic peptides in heart failure","volume":"8","author":"Chen","year":"2006","journal-title":"Eur Heart J Suppl"},{"issue":"21","key":"10.1002\/jps.23910_bb0060","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1161\/01.CIR.0000070547.88378.EA","article-title":"Effects of intravenous nesiritide on human coronary vasomotor regulation and myocardial oxygen uptake","volume":"107","author":"Michaels","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/jps.23910_bb0065","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","article-title":"The role of natriuretic peptides in cardioprotection","volume":"69","author":"Nishikimi","year":"2006","journal-title":"Cardiovasc Res"},{"issue":"2","key":"10.1002\/jps.23910_bb0070","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1006\/bbrc.1994.2772","article-title":"C-type natriuretic peptide inhibits intimal thickening of rabbit carotid-artery after balloon catheter injury","volume":"205","author":"Shinomiya","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/jps.23910_bb0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1937-6448(08)00803-4","article-title":"Natriuretic peptides in vascular physiology and pathology","volume":"268","author":"Woodard","year":"2008","journal-title":"Int Rev Cell Mol Biol"},{"issue":"3","key":"10.1002\/jps.23910_bb0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.18388\/abp.2000_3975","article-title":"Particulate guanylyl cyclases: Multiple mechanisms of activation","volume":"47","author":"Kobialka","year":"2000","journal-title":"Acta Biochim Pol"},{"issue":"3","key":"10.1002\/jps.23910_bb0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol Ther"},{"issue":"3","key":"10.1002\/jps.23910_bb0090","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0006-291X(05)80284-0","article-title":"Structural requirements of C-type natriuretic peptide for elevation of cyclic-GMP in cultured vascular smooth-muscle cells","volume":"183","author":"Furuya","year":"1992","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1002\/jps.23910_bb0095","first-page":"1428","article-title":"Bioactivity and metabolism of C-type natriuretic pepitde in normal man","volume":"78","author":"Hunt","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1002\/jps.23910_bb0100","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jacc.2004.10.067","article-title":"C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction","volume":"45","author":"Socki","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1002\/jps.23910_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2012.03.002","article-title":"Novel therapies in acute and chronic heart failure","volume":"135","author":"Aronson","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1002\/jps.23910_bb0110","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nrd3431","article-title":"Novel therapeutic targets for the treatment of heart failure","volume":"10","author":"Tamargo","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"23","key":"10.1002\/jps.23910_bb0115","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1093\/eurheartj\/ehl337","article-title":"Haemodynamic and clinical effects of ularitide in decompensated heart failure","volume":"27","author":"Mitrovic","year":"2006","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1002\/jps.23910_bb0120","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/hc0802.104282","article-title":"Maximizing the natriuretic peptide system in experimental heart failure\u2014Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition","volume":"105","author":"Chen","year":"2002","journal-title":"Circulation"},{"issue":"16","key":"10.1002\/jps.23910_bb0125","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1136\/hrt.2008.153916","article-title":"Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: A proof of concept study","volume":"95","author":"Chen","year":"2009","journal-title":"Heart"},{"issue":"9605","key":"10.1002\/jps.23910_bb0130","first-page":"2102","article-title":"Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomised trials","volume":"370","author":"Kitakaze","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/jps.23910_bb0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.ATV.zhq0504.7914","article-title":"Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure","volume":"24","author":"Schmitt","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1002\/jps.23910_bb0140","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0928-0987(01)00095-1","article-title":"Modeling and comparison of dissolution profiles","volume":"13","author":"Costa","year":"2001","journal-title":"Eur J Pharm Sci"},{"issue":"1\u20132","key":"10.1002\/jps.23910_bb0145","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijpharm.2011.07.020","article-title":"Effects of amphiphilic PCL\u2013PEG\u2013PCL copolymer addition on 5-fluorouracil release from biodegradable PCL films for stent application","volume":"419","author":"Lu","year":"2011","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1002\/jps.23910_bb0150","doi-asserted-by":"crossref","DOI":"10.1088\/1748-6041\/6\/2\/025003","article-title":"A poly(epsilon-caprolactone) device for sustained release of an anti-glaucoma drug","volume":"6","author":"Natu","year":"2011","journal-title":"Biomed Mater"},{"issue":"6","key":"10.1002\/jps.23910_bb0155","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/mp700097x","article-title":"Anomalous release of hydrophilic drugs from poly(epsilon-caprolactone) matrices","volume":"4","author":"Rosenberg","year":"2007","journal-title":"Mol Pharm"},{"issue":"1\u20133","key":"10.1002\/jps.23910_bb0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bpc.2007.09.004","article-title":"Protein precipitation and denaturation by dimethyl sulfoxide","volume":"131","author":"Arakawa","year":"2007","journal-title":"Biophys Chem"},{"issue":"0","key":"10.1002\/jps.23910_bb0165","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cis.2006.05.018","article-title":"Effect of salts and organic additives on the solubility of proteins in aqueous solutions","volume":"123\u2013126","author":"Ruckenstein","year":"2006","journal-title":"Adv Colloid Interface Sci"},{"issue":"1\u20132","key":"10.1002\/jps.23910_bb0170","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijpharm.2007.01.041","article-title":"Factors affecting protein release behavior from surfactant\u2013protein complexes under physiological conditions","volume":"338","author":"Yoshiura","year":"2007","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"10.1002\/jps.23910_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2009.12.027","article-title":"The interplay of membrane formation and drug release in solution-cast films of polylactide polymers","volume":"388","author":"Ma","year":"2010","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1002\/jps.23910_bb0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2010.05.017","article-title":"5-Fluorouracil-loaded multilayered films for drug controlled releasing stent application: Drug release, microstructure, and ex vivo permeation behaviors","volume":"146","author":"Lei","year":"2010","journal-title":"J Control Release"},{"issue":"5","key":"10.1002\/jps.23910_bb0185","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.actbio.2011.02.002","article-title":"The effect of polyethylene glycol structure on paclitaxel drug release and mechanical properties of PLGA thin films","volume":"7","author":"Steele","year":"2011","journal-title":"Acta Biomater"},{"issue":"1\u20132","key":"10.1002\/jps.23910_bb0190","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijpharm.2009.12.030","article-title":"Anti-atherosclerotic peptide delivery from a photocrosslinkable biodegradable network","volume":"388","author":"Amsden","year":"2010","journal-title":"Int J Pharm"},{"issue":"8","key":"10.1002\/jps.23910_bb0195","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s11095-007-9271-y","article-title":"New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants","volume":"24","author":"Herrmann","year":"2007","journal-title":"Pharm Res"},{"issue":"2","key":"10.1002\/jps.23910_bb0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2006.11.001","article-title":"Mechanisms controlling protein release from lipidic implants: Effects of PEG addition","volume":"118","author":"Herrmann","year":"2007","journal-title":"J Control Release"},{"issue":"1","key":"10.1002\/jps.23910_bb0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejpb.2011.01.003","article-title":"Zero-order release of 5-fluorouracil from PCL-based films featuring trilayered structures for stent application","volume":"78","author":"Lei","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"3\u20134","key":"10.1002\/jps.23910_bb0210","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.colsurfb.2005.04.010","article-title":"Effect of poly(ethylene oxide) on the release behaviors of poly(epsilon-caprolactone) microcapsules containing erythromycin","volume":"43","author":"Park","year":"2005","journal-title":"Colloid Surf B Biointerfaces"},{"issue":"10","key":"10.1002\/jps.23910_bb0215","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/pat.517","article-title":"Poly(caprolactone triol) as plasticizer agent for cellulose acetate films: Influence of the preparation procedure and plasticizer content on the physico-chemical properties","volume":"15","author":"Meier","year":"2004","journal-title":"Polym Adv Technol"},{"issue":"2\u20133","key":"10.1002\/jps.23910_bb0220","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0168-3659(97)00065-5","article-title":"The effect of size, charge and cyclization of model peptides on their in vitro release from DL-PLGA microspheres","volume":"49","author":"Okumu","year":"1997","journal-title":"J Control Release"},{"issue":"6","key":"10.1002\/jps.23910_bb0225","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1021\/mp200513b","article-title":"A new insight for an old system: Protein-PEG colocalization in relation to protein release from PCL\/PEG blends","volume":"8","author":"Liu","year":"2011","journal-title":"Mol Pharm"},{"issue":"6","key":"10.1002\/jps.23910_bb0230","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0959-440X(01)00278-0","article-title":"Proteins in organic solvents","volume":"11","author":"Mattos","year":"2001","journal-title":"Curr Opin Struct Biol"},{"issue":"10","key":"10.1002\/jps.23910_bb0235","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1023\/A:1026498209874","article-title":"Protein instability in poly(lactic-co-glycolic acid) microparticles","volume":"17","author":"van de Weert","year":"2000","journal-title":"Pharm Res"},{"issue":"3","key":"10.1002\/jps.23910_bb0240","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0939-6411(98)00011-3","article-title":"Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: Effect of the protein and polymer properties and of the co-encapsulation of surfactants","volume":"45","author":"Blanco","year":"1998","journal-title":"Eur J Pharm Biopharm"},{"issue":"2\u20133","key":"10.1002\/jps.23910_bb0245","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-3659(01)00292-9","article-title":"Pegylation enhances protein stability during encapsulation in PLGA microspheres","volume":"73","author":"Diwan","year":"2001","journal-title":"J Control Release"},{"issue":"3","key":"10.1002\/jps.23910_bb0250","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0168-3659(01)00232-2","article-title":"Development and characterization of a novel peroral peptide drug delivery system","volume":"71","author":"Dorkoosh","year":"2001","journal-title":"J Control Release"},{"issue":"3","key":"10.1002\/jps.23910_bb0255","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0168-3659(02)00261-4","article-title":"Controlled release of an osteogenic peptide from injectable biodegradable polymeric composites","volume":"84","author":"Hedberg","year":"2002","journal-title":"J Control Release"},{"issue":"2","key":"10.1002\/jps.23910_bb0260","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jbm.a.31635","article-title":"Maintaining bioactivity of NGF for controlled release from PLGA using PEG","volume":"86A","author":"Johnson","year":"2008","journal-title":"J Biomed Mater Res Part A"},{"key":"10.1002\/jps.23910_bb0265","author":"Burnett","year":"2011"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915305876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915305876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T22:57:12Z","timestamp":1597532232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915305876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0022354915305876"],"URL":"https:\/\/doi.org\/10.1002\/jps.23910","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}